HPH-15 is an anti-migration compound that inhibits cell migration by binding to hnRNP U or suppressing TGF-β signaling. In addition, HPH-15 can also inhibit epithelial-mesenchymal transition (EMT). HPH-15 holds promise for research in the fields of anti-tumor metastasis and anti-fibrosis.

HNC-1664 is the orally active inhibitor for RNA-dependent RNA polymerase (RdRP). HNC-1664 exhibits broad-spectrum antiviral activity against coronavirus (SARS-CoV-2 wildtype and its mutants XBB.1.18, HK.3.1, BF.7.14, BA.1HCoV-229E, HCoV-OC43) and arenavirus. HNC-1664 exhibits anti-infectious activity in SARS-CoV-2 Delta infected mouse models.

GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer.

ddATP (2',3'-Dideoxyadenosine 5'-triphosphate) tetrasodium is an active metabolite of 2',3'-dideoxyadenosine and an inhibitor of chain elongation by DNA polymerase (DNA polymerase). ddATP tetrasodium can be used in Sanger sequencing and research related to viral infections.

Clofarabine-5'-triphosphate is the metabolite of Clofarabine by deoxycytidine kinase (dCK) phosphorylation. Clofarabine-5'-triphosphate exhibits cytotoxicity in cancer cells through inhibition of DNA synthesis and DNA repair.

Clofarabine-5'-diphosphate trisodium (Clofarabine-DP trisodium) is the trisodium salt form of Clofarabine-5'-diphosphate. Clofarabine-5'-diphosphate trisodium is the metabolite of ClofarabineA0005) by deoxycytidine kinase (dCK) phosphorylation. Clofarabine-5'-diphosphate trisodium can be further phorphorylated into Clofarabine-5'-triphosphate, and exhibits cytotoxicity in cancer cells through inhibition of DNA synthesis and DNA repair.

Clofarabine-5'-diphosphate (Clofarabine-DP) is the metabolite of Clofarabine by deoxycytidine kinase (dCK) phosphorylation. Clofarabine-5'-diphosphate can be further phorphorylated into Clofarabine-5'-triphosphate, and exhibits cytotoxicity in cancer cells through inhibition of DNA synthesis and DNA repair.

Ap4dT is an inhibitor for human adenylate kinase isozyme 1 (hAK1), that inhibits the ATP and ADP synthesis with IC50s of 42 μM and 38 μM.

AHL-Pu-2 is the clickable electrophilic purine. AHL-Pu-2 can be used to directly quantify protein-RNA interactions on proteins through photoaffinity competition with 4-thiouridine (4SU)-labeled RNA in cells.

Adenosyl-(3′→5′)-uridine (ApU) is a nucleotide, which is composed of an adenine base and a uracil sugar molecule through a 3'-5' phosphodiester bond. Adenosyl-(3′→5′)-uridine (ApU) participates in the biological processes, such as gene expression regulation, signal transduction, and protein synthesis.

2'-(2-Nitrobenzyl)-ATP is an rATP analog. 2'-(2-Nitrobenzyl)-ATP acts as a transcription terminator, inhibiting further RNA chain elongation by T7 RNA polymerase.

NNISC-2 (compound 4) is a DNA intercalator-linker conjugate of Naph-Se-TMZ, which is composed of DNA intercalator Nitro-Naphthalimide-C2-acylamide and a linker.

Nitro-Naphthalimide-C2-acylamide is a DNA intercalator. Nitro-Naphthalimide-C2-acylamide can be used for the synthesis of PROTAC-like Naph-Se-TMZ can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy.

HLDA-212 (Compound 43) is a bifunctional small molecule targeting HaloTag-tagged protein (Target Protein, TP) and Aurora kinase A/B (AURKA/B, Effector Protein, EP). HLDA-212 binds to TP and EP to form a stable ternary complex (TP:RIPTAC:EP), inhibiting the cell-survival function of EP and inducing apoptosis in TP-expressing cancer cells. HLDA-212 shows antiproliferative activity (GI50 of 0.011 μM) in 293_HFL cells. HLDA-212 is promising for research of cancers with high TP expression (such as prostate cancer and hematological malignancies).

YY2201 is a highly potent and selective ATR inhibitor with an IC50 of 8 nM. YY2201 shows >200-fold more selective for ATR than mTOR. YY2201 inhibits tumor progression in broad-spectrum cancer types (such as lung cancer).

(S)-WSD0628 (Compound 28) is the S-isomer of WSD0628. 4-Methylphenoxyacetic acid-Oxindole-CF3 can be utilized in PROTAC synthesis.

OSI-7904L (GW1843) is a noncompetitive inhibitor of thymidylate synthase (TS). OSI-7904L is an antifolate compound and a substrate for folylpolyglutamate synthetase. OSI-7904L has cytotoxicity against solid tumor lines, and the toxicity can be selectively blocked by folic acid.

Thioparib is a next-generation potent, orally bioavailable pan-PARP inhibitor with IC50 of 0.13/0.006 nM (PARP1/2), overcomes multiple PARPi resistance both in vitro and in vivo.

Allopole-A is the first allosteric, specfic inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1) with IC50 of 2.5 nM in FP-based assays, Allopole-A is the active form of Allopole.

Cyclin K degrader DS17 is a selective cyclin K molecular glue degrader with TR-FRET EC50 of 19 nM.

SW394703 is a novel DDB1-dependent molecular glue degrader for cyclin K, SW394703 is toxic to HCT116 cells (IC50=1.2 uM).

GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM; displays >100-fold selectivity against the closely related Aurora A-TPX2 complex(IC50=490 nM).

TH 287 is a first-in-class MTH1 inhibitor (IC50 value 5.0 nM) that selectively and effectively kills U2OS and other cancer cell lines, with considerably less toxicity towards several primary or immortalized cells.

PIP-199 is a selective inhibitor of RMI (RecQ-mediated genome instability protein) core complex/MM2 interaction, with an IC50 of 36 μM. MM2 is the binding site of RMI complex on Fanconi anemia complementation group M protein (FANCM). PIP-199 can be used for the research of sensitizing resistant tumors to DNA crosslinking chemotherapeutics.

TH588 represents a highly selective and cell-permeable small molecule inhibitor targeting MTH1 (NUDT1), a member of the nudix hydrolase family, with potent inhibitory activity (IC₅₀ ≈5 nM).

RX-3117 is an orally available and potent DNA synthesis inhibitor with potential antineoplastic activity.

​​Flavopiridol hydrochloride​​ is a potent pan-cyclin-dependent kinase (CDK) inhibitor with a unique ATP-competitive mechanism.

NCGC00131308 is a small molecule inhibitor that effectively disrupts IQGAP1-Cdc42 interaction in breast cancer cells, shows EC50 of 4.47 uM in biochemical HTRF assays.

XPW1 is a potent and selective CDK9 inhibitor with excellent anti-ccRCC activity and low toxicity.

A83B4C63 is a highly potent small-molecule inhibitor targeting the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP), exhibiting strong binding affinity with a ​Kd of 80 nM. Due to its limited aqueous solubility, A83B4C63 was formulated into ​nano-encapsulated carriers, enhancing its therapeutic potential—particularly in ​PTEN-deficient colorectal cancer (CRC).